Hyperliquid Strategies Inc and Sonnet BioTherapeutics Holdings, Inc. Announce Closing of Business Combination
Trading on The Nasdaq Capital Market under the ticker symbol “PURR”
| Date | Form | Description | XBRL | Pages | |
|---|---|---|---|---|---|
| 12/19/17 | CORRESP | A correspondence can be sent as a document with another submission type or can be sent as a separate submission. |
|
2 | |
| 12/13/17 | UPLOAD | SEC-generated letter |
|
1 | |
| 12/04/17 | 8-K | Current report filing |
|
4 | |
| 12/01/17 | S-3 | Registration statement for specified transactions by certain issuers |
|
27 | |
| 11/13/17 | 8-K | Current report filing |
|
33 | |
| 11/13/17 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) |
|
   |
53 |
| 10/27/17 | EFFECT | Notice of Effectiveness |
|
1 | |
| 10/24/17 | CORRESP | A correspondence can be sent as a document with another submission type or can be sent as a separate submission. |
|
2 | |
| 10/24/17 | S-3/A | Registration statement for specified transactions by certain issuers |
|
25 | |
| 10/13/17 | 8-K | Current report filing |
|
68 |
